Format

Send to

Choose Destination
Ann Intern Med. 2009 Jun 2;150(11):803-8. Epub 2009 Apr 20.

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

Author information

1
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. kerunit@mayo.edu

Erratum in

  • Ann Intern Med. 2009 Jul 21;151(2):144.

Abstract

Some diabetes guidelines set low glycemic control goals for patients with type 2 diabetes mellitus (such as a hemoglobin A(1c) level as low as 6.5% to 7.0%) to avoid or delay complications. Our review and critique of recent large randomized trials in patients with type 2 diabetes suggest that tight glycemic control burdens patients with complex treatment programs, hypoglycemia, weight gain, and costs and offers uncertain benefits in return. We believe clinicians should prioritize supporting well-being and healthy lifestyles, preventive care, and cardiovascular risk reduction in these patients. Glycemic control efforts should individualize hemoglobin A(1c) targets so that those targets and the actions necessary to achieve them reflect patients' personal and clinical context and their informed values and preferences.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center